GGrantIndex
Sort

64,565 grants matching drug discovery

Neuroprotection in Stroke Drug Development

$1,070,000
Ruben J. Boado · Armagen Technologies, Inc. · R44 · FY2006 · NS

Optimizing Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Malaria

$1,069,709
Ian Cyril Bathurst · Medicines For Malaria Venture · U01 · FY2008 · AI

Novel oxadiazols for the treatment of drug-resistant gram-positive bacteria

$1,069,649
Mayland F Chang · University Of Notre Dame · R01 · FY2010 · AI

2/2-Rare Bipolar Loci Identification Through Synaptome Sequencing.

$1,069,587
William Richard McCombie · Cold Spring Harbor Laboratory · R01 · FY2012 · MH

Aging, Oxidative Stress and Cell Death

$1,069,269
Brian A. Herman · University Of Texas Hlth Science Center · P01 · FY2009 · AG

EFRI-CBE Topic B: Biofunctionalized Devices - On Chip Signaling and "Rewiring" Bacterial Cell-Cell Communication

$1,068,844
William E Bentley · University Of Maryland, College Park · · FY2010 · ENG

Brain Glycogen-Metabolism,Mechanisms, and Therapeutic Potential

$1,068,798
Matthew S. Gentry · University Of Florida · R35 · FY2025 · NS

A new high-throughput gastrointestinal tract explant platform for drug formulation discovery and metabolic disease modulation

$1,068,674
Robert S Langer · Massachusetts Institute Of Technology · R01 · FY2021 · EB

Development of mGluR5 Antagonists to Treat Fragile X Syndrome and Autism

$1,068,100
Randall L Carpenter · Seaside Therapeutics, Llc · U01 · FY2009 · MH

Development of mGluR5 Antagonists to Treat Fragile X Syndrome and Autism

$1,068,100
Randall L Carpenter · Seaside Therapeutics, Llc · U01 · FY2008 · MH

Discovery and Translational Core Services

$1,068,010
Gerald A Beltz · Harvard Medical School · U19 · FY2014 · AI

Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway

$1,068,000
Michael J Eck · Dana-Farber Cancer Inst · R35 · FY2021 · CA

Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway

$1,068,000
Michael J Eck · Dana-Farber Cancer Inst · R35 · FY2025 · CA

Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway

$1,068,000
Michael J Eck · Dana-Farber Cancer Inst · R35 · FY2020 · CA

Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes

$1,068,000
John M Maris · Children'S Hosp Of Philadelphia · R35 · FY2025 · CA

Discovery of cGAS-like signaling enzymes in innate immunity and disease

$1,068,000
Philip J Kranzusch · Dana-Farber Cancer Inst · DP2 · FY2024 · GM

Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathway

$1,068,000
Michael J Eck · Dana-Farber Cancer Inst · R35 · FY2019 · CA

Advanced Mass Spectrometry Facility

$1,067,912
David Anderson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIC · FY2010 · DK

Vaccines and Therapeutics for Nipah and Hendra virus

$1,067,628
Christopher Broder · Henry M. Jackson Fdn For The Adv Mil/Med · U01 · FY2011 · AI

Antidotes to Anthrax Lethal Factor Intoxication

$1,067,549
Alan Thomas Johnson · Panthera Biopharma, Llc · U01 · FY2009 · AI

Molecular Targets Phase III CoBRE

$1,067,488
Donald M Miller · University Of Louisville · P30 · FY2015 · GM

Structure and Function of Neurotransmitter Transporters

$1,067,481
Harel Weinstein · Weill Medical Coll Of Cornell Univ · P01 · FY2009 · DA

Vascular remodeling in patients with rare genetic disorders

$1,067,418
Manfred Boehm · National Heart, Lung, And Blood Institute · ZIA · FY2015 · HL

Development Of Theoretical Methods For Studying Biological Macromolecules

$1,067,238
Bernard R Brooks · National Heart, Lung, And Blood Institute · ZIA · FY2020 · HL

Antisense Oligonucleotide (ASO) Development for Rare and Neglected Diseases

$1,066,904
Elizabeth Ottinger · National Center For Advancing Translational Sciences · ZIA · FY2024 · TR